Anxiety is a risk prognosis factor for hepatocellular carcinoma with portal vein tumor thrombus who underwent hepatic arterial infusion chemotherapy: a propensity score-matching cohort study

焦虑是接受肝动脉灌注化疗的伴有门静脉癌栓的肝细胞癌患者的危险预后因素:一项倾向评分匹配队列研究

阅读:1

Abstract

BACKGROUND: Increasing evidence indicates that psychological factors play a role in tumor progression. This study aims to explore the impact of anxiety disorder on the prognosis of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) who underwent hepatic arterial infusion chemotherapy (HAIC). METHODS: A propensity score-matching cohort study was conducted in 68 HCC patients with PVTT who underwent HAIC between January 2020 and December 2023. The anxiety situation was evaluated using the Hamilton Anxiety Rating Scale before HAIC. The objective response rate, overall survival (OS), progression-free survival, and adverse events were compared between the different anxiety score groups. Using Cox proportional hazards models for univariate and multivariate analysis to explore the risk factors of OS. RESULTS: No statistical difference was found in the tumor response, treatment-related adverse events, and PFS between the two groups before and after PSM. Compared with low anxiety scores patients, the OS of obvious anxiety patients was shorter (hazard ratio [HR] = 1.606; 95%CI: 0.868-2.973; P = 0.116). The univariate and multivariate analysis showed that BMI (HR = 1.174, 95%CI: 1.044-1.320; P = 0.007), high anxiety score (HR = 2.769, 95%CI: 1.289-5.947; P = 0.007), and serum ammonia (HR = 1.059; 95%CI: 1.032-1.086; P < 0.001) were independent risk factors of OS. CONCLUSIONS: Our study reveals that elevated anxiety scores in HCC patients with PVTT correlated with poor prognosis, indicating that it's a potential prognostic marker. The high anxiety score, BMI, and serum ammonia were independent risk factors of OS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。